• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

    0.3556 +0.0239 (+7.21%)
    Delayed Quote Updated: 11:14 AM EDT, Oct 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Heron Therapeutics, Inc. - Common Stock

    News headline image
    Heron Therapeutics Announces Second Quarter 2026 Financial Results
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    U.S. District Court Issues Decision Regarding CINVANTI® Patents
    After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal 
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    Heron Therapeutics Inc. (NASDAQ: HRTX) Near the Top of Equities by Percentage Gain on 4/23
    Via Investor Brand Network
    News headline image
    Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
    From Heron Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.